Lineage Cell Therapeutics (LCTX) Shares Outstanding (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Shares Outstanding (Entity) of $249.3 million for Q1 2026, up 9.17% year-over-year from $228.4 million in Q1 2025, and up 2.54% quarter-over-quarter from $243.1 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Shares Outstanding (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $249.3 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 9.17% year-over-year to $249.3 million; the TTM figure through Mar 2026 stood at $249.3 million (up 9.17% YoY), while the FY2025 annual figure was $243.1 million, up 10.3% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $249.3 million, up from $243.1 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $249.3 million in Q1 2026, with the low at $169647.0 in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $188.8 million (2024), against an average of $186.5 million.
- Peak annual rise in Shares Outstanding (Entity) reached 104094.85% in 2022, while the deepest fall reached 99.9% in 2022.
- Lineage Cell Therapeutics' Shares Outstanding (Entity) stood at $170.1 million in 2022, then climbed by 2.88% to $175.0 million in 2023, then increased by 25.96% to $220.4 million in 2024, then climbed by 10.3% to $243.1 million in 2025, then grew by 2.54% to $249.3 million in 2026.
- Business Quant data shows LCTX's Shares Outstanding (Entity) at $249.3 million in Q1 2026, $243.1 million in Q4 2025, and $230.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 249.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 249.50 Mn |
| Mar 31, 2026 | 245.03 Mn |
| Dec 31, 2025 | 230.12 Mn |
| Sep 30, 2025 | 228.85 Mn |
| Jun 30, 2025 | 228.36 Mn |
| Mar 31, 2025 | 226.05 Mn |
| Dec 31, 2024 | 200.19 Mn |
| Sep 30, 2024 | 188.84 Mn |
| Jun 30, 2024 | 188.81 Mn |
| Mar 31, 2024 | 182.91 Mn |
| Dec 31, 2023 | 172.66 Mn |
| Sep 30, 2023 | 174.87 Mn |
| Jun 30, 2023 | 170.59 Mn |
| Mar 31, 2023 | 170.13 Mn |
| Dec 31, 2022 | 169.79 Mn |
| Sep 30, 2022 | 169.79 Mn |
| Jun 30, 2022 | 169.73 Mn |
| Mar 31, 2022 | 169,647.00 |
| Dec 31, 2021 | 164,502.00 |
| Sep 30, 2021 | 167.62 Mn |